Cargando…

Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus

Objective The adverse effects of selective sodium-glucose co-transporter 2 (SGLT2) inhibitors generally appear within about two or three months after treatment initiation in Japan. Therefore, we investigated the impact of tofogliflozin, a class of SGLT2 inhibitors, on glycemic control and body compo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirose, Sachie, Nakajima, Shinsuke, Iwahashi, Yasuyuki, Seo, Akane, Takahashi, Tetsuya, Tamori, Yoshikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173489/
https://www.ncbi.nlm.nih.gov/pubmed/27853064
_version_ 1782484316108881920
author Hirose, Sachie
Nakajima, Shinsuke
Iwahashi, Yasuyuki
Seo, Akane
Takahashi, Tetsuya
Tamori, Yoshikazu
author_facet Hirose, Sachie
Nakajima, Shinsuke
Iwahashi, Yasuyuki
Seo, Akane
Takahashi, Tetsuya
Tamori, Yoshikazu
author_sort Hirose, Sachie
collection PubMed
description Objective The adverse effects of selective sodium-glucose co-transporter 2 (SGLT2) inhibitors generally appear within about two or three months after treatment initiation in Japan. Therefore, we investigated the impact of tofogliflozin, a class of SGLT2 inhibitors, on glycemic control and body composition during this period in Japanese patients with type 2 diabetes mellitus. Methods This single-arm open-label study enrolled 20 patients. Patients received tofogliflozin 20 mg once daily for 8 weeks. At week 8, changes from baseline in body weight, serum metabolic markers, and body composition were evaluated. Results A total of 17 patients completed the 8-week administration of tofogliflodin. No serious adverse events were noted. Hemoglobin A1c (HbA1c) decreased significantly, from 7.8% to 7.3% with 8-week administration of tofogliflozin. Both the body weight and body mass index (BMI) also decreased. In addition, a decreased renal function of the boundary zone and hemoconcentration were detected. As for body composition, the free fat mass, total body water, extracellular water and intracellular water were all decreased significantly. Interestingly, the amount of fat mass did not change. The degree of improvement in HbA1c was correlated with the baseline fat mass and BMI. Conclusion An eight-week administration of tofogliflozin improved glycemic control and reduced the body weight and free fat mass in type 2 diabetic patients without affecting the fat mass. In this period, the hematocrit level and renal function should be monitored to guard against hemoconcentration and renal impairment, respectively.
format Online
Article
Text
id pubmed-5173489
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-51734892016-12-27 Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus Hirose, Sachie Nakajima, Shinsuke Iwahashi, Yasuyuki Seo, Akane Takahashi, Tetsuya Tamori, Yoshikazu Intern Med Original Article Objective The adverse effects of selective sodium-glucose co-transporter 2 (SGLT2) inhibitors generally appear within about two or three months after treatment initiation in Japan. Therefore, we investigated the impact of tofogliflozin, a class of SGLT2 inhibitors, on glycemic control and body composition during this period in Japanese patients with type 2 diabetes mellitus. Methods This single-arm open-label study enrolled 20 patients. Patients received tofogliflozin 20 mg once daily for 8 weeks. At week 8, changes from baseline in body weight, serum metabolic markers, and body composition were evaluated. Results A total of 17 patients completed the 8-week administration of tofogliflodin. No serious adverse events were noted. Hemoglobin A1c (HbA1c) decreased significantly, from 7.8% to 7.3% with 8-week administration of tofogliflozin. Both the body weight and body mass index (BMI) also decreased. In addition, a decreased renal function of the boundary zone and hemoconcentration were detected. As for body composition, the free fat mass, total body water, extracellular water and intracellular water were all decreased significantly. Interestingly, the amount of fat mass did not change. The degree of improvement in HbA1c was correlated with the baseline fat mass and BMI. Conclusion An eight-week administration of tofogliflozin improved glycemic control and reduced the body weight and free fat mass in type 2 diabetic patients without affecting the fat mass. In this period, the hematocrit level and renal function should be monitored to guard against hemoconcentration and renal impairment, respectively. The Japanese Society of Internal Medicine 2016-11-15 /pmc/articles/PMC5173489/ /pubmed/27853064 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Hirose, Sachie
Nakajima, Shinsuke
Iwahashi, Yasuyuki
Seo, Akane
Takahashi, Tetsuya
Tamori, Yoshikazu
Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus
title Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus
title_full Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus
title_fullStr Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus
title_full_unstemmed Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus
title_short Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus
title_sort impact of the 8-week administration of tofogliflozin for glycemic control and body composition in japanese patients with type 2 diabetes mellitus
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173489/
https://www.ncbi.nlm.nih.gov/pubmed/27853064
work_keys_str_mv AT hirosesachie impactofthe8weekadministrationoftofogliflozinforglycemiccontrolandbodycompositioninjapanesepatientswithtype2diabetesmellitus
AT nakajimashinsuke impactofthe8weekadministrationoftofogliflozinforglycemiccontrolandbodycompositioninjapanesepatientswithtype2diabetesmellitus
AT iwahashiyasuyuki impactofthe8weekadministrationoftofogliflozinforglycemiccontrolandbodycompositioninjapanesepatientswithtype2diabetesmellitus
AT seoakane impactofthe8weekadministrationoftofogliflozinforglycemiccontrolandbodycompositioninjapanesepatientswithtype2diabetesmellitus
AT takahashitetsuya impactofthe8weekadministrationoftofogliflozinforglycemiccontrolandbodycompositioninjapanesepatientswithtype2diabetesmellitus
AT tamoriyoshikazu impactofthe8weekadministrationoftofogliflozinforglycemiccontrolandbodycompositioninjapanesepatientswithtype2diabetesmellitus